UK introduces Carevix medical device through partnership with AGHealth
In a significant step forward for women's healthcare in the UK, the Carevix device, an MHRA-approved non-traumatic suction cervical stabiliser, has made a remarkable impact. This innovative tool, introduced by ASPIVIX in partnership with AGHealth, is transforming the experience and outcomes of gynaecological procedures.
Peterborough City Hospital was the first UK hospital to adopt Carevix in 2024 through the Carevix Ambassador Program. The device, according to Charlotte Barker, Director of AGHealth, offers a more dignified, pain-conscious option for gynaecological procedures.
The Carevix Ambassador Program brought together 21 centres of excellence across 9 countries to evaluate the device in real-world settings. The results, as detailed in the Carevix Ambassador Program Report 2024-2025, have been overwhelmingly positive.
One of the key benefits of Carevix is its ability to substantially reduce pain during procedures. Studies, including the ADVANCE Women Study, a single-blinded, randomised, multicentre comparative trial, have shown up to a 73% reduction in pain compared to standard tenaculums. This facilitates a more comfortable experience for women undergoing cervical procedures.
In addition, Carevix has demonstrated a marked reduction in bleeding. Reductions of up to 78% have been observed, which not only improves patient comfort but may also reduce procedure-related complications and recovery time.
The non-traumatic suction mechanism of Carevix stabilises the cervix gently without the tissue trauma commonly associated with traditional tenaculums, leading to less discomfort and bleeding.
These improvements represent a shift towards more patient-centered gynecological care, aligning with contemporary goals to minimise procedural pain and trauma, thus enhancing overall women's wellbeing during cervical interventions.
Mathieu Horras, CEO & Co-Founder of ASPIVIX, expresses pride in bringing Carevix to the UK in partnership with AGHealth. He emphasises that Carevix provides a game-changing solution that improves both patient comfort and clinical confidence.
Results from the Carevix Ambassador Program showed high satisfaction among both clinicians and patients. 96% of clinicians found Carevix easy to use, while 94% of overall patient satisfaction was reported.
Both Charlotte Barker and Mathieu Horras affirm Carevix's strong clinical results. They highlight ASPIVIX's shared commitment with AGHealth to advancing women's health through innovation.
Fear of pain during IUD insertion remains a major barrier to adoption, affecting 30% to 45% of women globally, an estimated 120 million women each year. With the introduction of Carevix, this barrier is being addressed, offering a more dignified, pain-conscious, and less traumatic option for gynaecological procedures.
[1] Carevix Ambassador Program Report 2024-2025 [2] ADVANCE Women Study [3] MHRA Approval for Carevix in the United Kingdom
- The latest femtech news highlights the positive impact of the Carevix device, a non-traumatic suction cervical stabiliser, in transforming women's health during gynaecological procedures.
- Medical plastics have played a crucial role in the success of Carevix, as its design uses medical-grade materials to offer a more pain-conscious option for handling medical-conditions related to women's health.
- As more hospitals adopt Carevix, the health-and-wellness industry is moving toward a future where innovative technologies like this one facilitate a more comfortable experience for women during cervical procedures, thereby enhancing their overall wellbeing.
